+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are comparing the effectiveness of two combinations of drugs, teclistamab with daratumumab and lenalidomide Tec-DR, and talquetamab with daratumumab and lenalidomide Tal-DR, against the combination of daratumumab, lenalidomide, and dexamethasone DRd in adults with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. This Phase 3 trial focuses on evaluating treatment outcomes and survival rates over an extended period. Participants will be randomly assigned to one of three groups one receiving teclistamab by subcutaneous injection combined with daratumumab and oral lenalidomide another receiving talquetamab by subcutaneous injection combined with daratumumab and lenalidomide and the third receiving daratumumab by subcutaneous injection along with oral lenalidomide and dexamethasone, which may be given orally or intravenously. Treatments will be administered according to protocol, with close monitoring throughout the study. During the study, participants will undergo regular evaluations over up to nine years, including assessments of disease progression, survival, response to treatment, and quality of life using various questionnaires. Safety will be monitored through laboratory tests, physical exams, vital signs, electrocardiograms, and tracking of any adverse events. Researchers will also measure drug concentrations and immune responses to the study drugs. Participation may last until disease progression, death, or the end of the study period.

Age: 18Years +All GendersPhase 3
270 locations
A

Actively Recruiting

Researchers are studying how art therapy affects emotional expression and regulation in military service members with posttraumatic stress symptoms. The study aims to understand the neurological systems involved by using brain scans and self-assessment questionnaires. This research is conducted within the Military Health System where art therapy is a common treatment but lacks thorough scientific evaluation. Participants will attend a total of eleven sessions over six to eight months. The first session includes an interview, self-assessment questionnaires, and a brain MRI scan while viewing neutral and negative images. Then, participants take part in eight one-hour individual art therapy sessions with a certified art therapist. The tenth session repeats the questionnaires and MRI scan, and the final session is a virtual interview conducted three months after the tenth visit. Throughout the study, participants will complete various questionnaires measuring symptoms and traits related to posttraumatic stress, anxiety, stress, and emotional regulation. Brain activity during tasks will be assessed through functional neuroimaging. The research also monitors potential emotional distress during sessions and collects qualitative feedback. Overall participation lasts up to eight months with follow-up to evaluate lasting effects.

Age: 18Years - 64YearsAll GendersPhase Not Applicable
2 locations
I

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Lacripep, an eyedrop medication, for repairing superficial corneal injuries after Photorefractive keratectomy PRK. This study focuses on improving healing of the cornea, the clear tissue covering the front of the eye, which can be damaged by trauma or surgery. Participants include active-duty military members or their dependents eligible for care at a military medical center. Participants will receive Lacripep in one eye and a placebo in the other eye simultaneously. The study measures how well Lacripep promotes corneal wound healing and maintains ocular surface health following PRK surgery. The treatment effects will be assessed over several months with evaluations at 4 and 7 days post-surgery, then at 1, 3, and 6 months. This phase 2 trial involves a single group receiving both treatments concurrently. During the study, participants will undergo regular assessments including epithelial thickness measurements to evaluate healing. Safety monitoring will occur from enrollment until the end of treatment at 6 months. Participants must be able to attend follow-up visits during this period. The main outcome measured is the effectiveness of Lacripep in corneal repair, along with monitoring for any side effects or safety concerns throughout the study duration.

Age: 21Years - 55YearsAll GendersPhase 2
1 location
P

Actively Recruiting

Researchers are conducting a phase 3 clinical trial comparing two treatment combinations for adults with ER-positive, HER2-negative advanced breast cancer who have not received prior systemic anti-cancer treatment for this condition. The study aims to evaluate the effectiveness and safety of palazestrant combined with ribociclib versus letrozole combined with ribociclib. Participants include men and women with locally advanced or metastatic breast cancer not suitable for curative therapy. Participants are randomly assigned to one of two groups. One group receives palazestrant 90 mg once daily, ribociclib 600 mg once daily on days 1-21 of a 28-day cycle, and a placebo matching letrozole daily. The other group receives letrozole 2.5 mg once daily, ribociclib 600 mg once daily on days 1-21 of a 28-day cycle, and a placebo matching palazestrant daily. Treatment cycles repeat every 28 days, and the study includes approximately 1,000 participants worldwide. During the study, participants will be monitored for disease progression and overall survival, with primary measurements taken from the date of randomization until disease progression or death, estimated up to 3.5 years. Safety, drug levels, and patient-reported health outcomes will be assessed regularly. The trial includes long-term follow-up for up to 5.5 years to evaluate overall survival. Participants will have scheduled visits for assessments and monitoring throughout their involvement in the trial.

Age: 18Years +All GendersPhase 3
200 locations
F

Actively Recruiting

Researchers are evaluating the safety and effectiveness of osimertinib tablets combined with Datopotamab Deruxtecan intravenous infusion compared to osimertinib alone as a first treatment for participants with locally advanced or metastatic non-small cell lung cancer NSCLC that has specific EGFR mutations Ex19del andor L858R. This global Phase III, open-label, randomized study includes participants who have not received prior therapy for advanced disease, aiming to assess treatment benefits over approximately 8 years. Participants are randomly assigned to one of two groups one group receives osimertinib 80 mg orally once daily plus Datopotamab Deruxtecan 6 mgkg by intravenous infusion every 3 weeks, while the other group receives osimertinib 80 mg orally once daily alone. Treatment continues until disease progression, unacceptable side effects, or other discontinuation reasons. Visits occur every 3 weeks during treatment, with additional assessments every 6 weeks from cycle 7 to cycle 17, then every 12 weeks for those on osimertinib alone or after discontinuing Datopotamab Deruxtecan. Participants will attend regular visits for treatment administration and assessments, including scans and laboratory tests to monitor disease status and safety. Researchers will measure progression-free survival, overall survival, response rates, and the impact on brain metastases over the study period. Pharmacokinetics and immunogenicity of the drugs will also be evaluated. The study includes continuous safety monitoring and may last up to 8 years, with visits and evaluations scheduled throughout treatment and follow-up.

Age: 18Years +All GendersPhase 3
167 locations
G

Actively Recruiting

Researchers are evaluating the efficacy and safety of Datopotamab Deruxtecan Dato-DXd combined with Rilvegostomig, or Rilvegostomig alone, compared with Pembrolizumab alone as first-line treatments for people with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC. Participants must have high PD-L1 expression tumor cells 50% and no actionable genomic mutations. This is a Phase III, randomized, open-label global study focusing on these treatments for this specific lung cancer type. Participants will be assigned to one of three groups one receiving Dato-DXd plus Rilvegostomig, another receiving Rilvegostomig alone, and a third receiving Pembrolizumab alone. All treatments are given by intravenous infusion every three weeks on Day 1 of each 21-day cycle. The study will monitor participants over several years to compare these therapies as first-line options. During the study, participants will undergo regular assessments including imaging and tumor sampling to measure progression-free survival and overall survival, focusing on those with TROP2 biomarker positivity. Other evaluations include response rates, duration of response, lung cancer symptoms, quality of life, physical functioning, pharmacokinetics, and immunogenicity over approximately 4 to 6 years. Safety monitoring and long-term follow-up are part of the participant involvement.

Age: 18Years +All GendersPhase 3
290 locations
S

Actively Recruiting

This research aims to evaluate the safety, effectiveness, and tolerability of two repetitive transcranial magnetic stimulation rTMS protocols targeting the dorsolateral prefrontal cortex to reduce depression symptoms in U.S. military members and veterans with a history of concussion or mild traumatic brain injury. The study uses a randomized, double-blind, Bayesian adaptive design to compare individualized connectome targeted accelerated intermittent Theta Burst Stimulation and scalp-targeted stimulation in this specific population. Participants are assigned randomly to one of three groups active rTMS with individualized connectome targeting, active rTMS with resting state functional MRI-based targeting, or a sham placebo rTMS group. These treatments are delivered as device-based brain stimulation therapies designed to assess their impact on depressive symptoms. The study includes an initial treatment phase followed by post-intervention assessments and a 6-month follow-up period. During the study, participants will undergo evaluations using the Montgomery-Asberg Depression Rating Scale to measure changes in depression symptoms from baseline through post-intervention and at 6 months. Additional assessments include self-reported depression scales, quality of life related to brain injury, PTSD symptoms, and brain connectivity via MRI scans. Researchers will monitor treatment compliance, adverse events, and overall safety throughout the trial, which lasts up to 6 months after final treatment.

Age: 18Years - 55YearsAll GendersPhase Not Applicable
3 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of sonesitatug vedotin combined with capecitabine, with or without rilvegostomig, as a first treatment option for adults with Claudin18.2-positive, HER2-negative advanced or metastatic gastric, gastroesophageal junction GEJ, and esophageal adenocarcinoma. This Phase III study includes two participant groups based on PD-L1 status and eligibility for immune checkpoint inhibitors ICI, aiming to provide treatment options tailored to these specific cancer characteristics. Participants receive different combinations of study drugs depending on their cohort Cohort 1 gets sonesitatug vedotin with rilvegostomig and capecitabine if PD-L1 positive and ICI eligible, while Cohort 2 receives sonesitatug vedotin with capecitabine if PD-L1 negative or ICI ineligible. Other treatment arms include combinations with nivolumab and zolbetuximab alongside standard chemotherapy regimens. All drugs are administered intravenously or orally as specified, with the study also assessing the clinical performance of diagnostic tests related to these treatments. Throughout the study, participants undergo regular assessments to monitor disease progression, survival, response to treatment, drug levels in the body, immune responses, and safety over approximately five years. Researchers use imaging and laboratory tests to evaluate tumors and organ function, and participants health status is closely observed. The study involves random assignment to treatment groups and includes ongoing safety and effectiveness evaluations during and after treatment.

Age: 18Years +All GendersPhase 3
314 locations